

Methamphetamine use disorder (+ HIV): Trials, Trends and Tribulations

Paxton Bach MD, MSc, ABIM, FRCPC Clinical Assistant Professor UBC Department of Medicine Vancouver, Canada

> WHAT-IF? Learning Collaborative September 11, 2019











Outline

- Background
- Physiology and health effects
- Epidemiology
- Treatment

Why the fuss?

- Higher rates of meth use in populations at risk for HIV
 - Up to 20% of MSM may report meth use within past 6mo ¹
- Meth use is associated with an increased risk of contracting HIV
 - Higher rates of risky behaviours (high risk injection and/or sexual practices)²
 - Impaired/altered immunity? ³
- Meth use is associated with worse HIV outcomes
 - Decreased ART adherence, slower rates of RNA suppression, decreased CD4 counts, poor overall health outcomes ^{3,4}

¹Shoptaw et al. *Addiction*, 2007. ²Degenhardt et al. *Int J Drug Policy*, 2009. ³Passaro et al. *J Neuroimmune Pharmacol*, 2015. ⁴Fairbairn et al. *Addict Behav*, 2011.



















Drug and Alcohol Dependence 190 (2018) 216-223



Contents lists available at ScienceDirect

Drug and Alcohol Dependence





HIV prevalence among MSM who primarily injected meth was almost 50% higher than among MSM who primarily injected other drugs, and this association was mediated by sexual risk.

ARTICLE INFO

Keywords: Methamphetamine MSM

PWID HIV

Chemsex

Sharing

ABSTRACT


Background and Aims: Men who have sex with men (MSM) and inject drugs are at risk for HIV infection. Although research exists on non-injection methamphetamine (meth) use and sexual risk among MSM, less is known about meth injection and its association with HIV infection among MSM who inject drugs.

Methods: We analyzed data from men aged ≥18 years who reported injecting drugs and male-to-male sexual contact. Men were recruited using respondent-driven sampling, interviewed, and tested for HIV during the 2012 and 2015 cycles of National HIV Behavioral Surveillance among persons who inject drugs. We included data from 8 cities where ≥ 10 MSM reported meth as the primary drug injected. We assessed differences in demographic characteristics, past 12 months risk behaviors, and HIV infection between MSM who primarily injected meth and those who primarily injected another drug.

Results: Among 961 MSM, 33.7% reported meth as the drug they injected most often. Compared to MSM who primarily injected other drugs, MSM who primarily injected meth were more likely to have had ≥ 5 condomless anal sex partners, have been diagnosed with syphilis, and were less likely to report sharing syringes. In multi-

iala analasia inicatina mathama arasistad mith haina 11117 nacitina (adimatad musualam

Background



Ephedra sinica

Methamphetamine



Methamphetamine powder

- PO or insufflated



Methamphetamine base

- PO or injected



Crystal methamphetamine

Smoked, insufflated or injected

Half-life for all 3 close to ~10 hours!

Ice, crystal, glass, speed, meth, jib, side, gak, chalk, crank, tina, go, geek, tweak, amp, P2P, zip, shards, goofball*

In the



Does more t



Narcolepsy, exhaustion, weight loss, schizophrenia, asthma, morphine addiction, barbiturate intoxication, alcoholism, excessive anaesthesia administration, migraine, heart block, myasthenia gravis, myotonia, enuresis, dysmenorrhea, Meniere's disease, colic, head injuries, infantile cerebral palsy, codeine addiction, tobacco smoking, pediatric behaviour issues, Parkinson's disease, epilepsy...

Benzedrine Inhaler

is available to

High Altitude Flying Person

Benardrine Inhaler is now an official item. Apery Air Forces.

It is available to Flight Surgeons for distrib abitude flying personnel, for refief of nata

Benzedrine Inhaler



Volatile Vasocoustrictor . . . Outstanding But, First and Foremosi, A Highly Effective Their

... WHEN YOU PRESCRIBE NEW

M()RNID

A new drug with specific effectiveness in nausea and vomiting of pregnancy, Mornidine eliminates the ordeal of morning sickness.

With its selective action on the vomiting center, or the medullary chemoreceptor "trigger zone," Mornidine possesses the advantages of the phenothiazine drugs without unwanted tranquilizing activity.

Doses of 5 to 10 mg., repeated at intervals of

day. In patients who are unable to retain oral medication when first seen, Mornidine may be administered intramuscularly in doses of 5 mg.

Mornidine is supplied as tablets of 5 mg. and as ampuls of 5 mg. (1 cc.).

> G.D. SEARLE & CO.OF CANADA LTD. 247 QUEEN ST., E., BRAMPTON, ONT.

For those who are depressed.

'Methedrine' dispels abnormal eraying for food, subtly elevates the mood.


'Methodrine's bound Methamphetamine Hydrochloride Tablets 5 mg., scored


six to eight hours, provide excellent relief all i CO. (U. S. A.) INC., Tuckahoe, New York



Physiology and effects

Pharmacology





Acute intoxication


- Mania/paranoia/psychosis
- Hypertension, agitation, sweating
- Skin-picking/formication (delusions of insects under the skin)
- Abnormal movement (choreoathetosis, ataxia)
- Miosis

Meth-associated health complications

Cardiac	Infectious	Hematologic	Gastrointestinal
Chest pain	HIV	Necrotizing angiitis	Acute liver injury
CAD	Viral hepatitis		Mesenteric infarction
Myocardial infarction		MSK	Ischemic colitis
Tachycardia	Neurologic	"Meth mouth"	Pancreatitis
Hypertension	ICH	Rhabdomyolysis	
Dysrhythmias	Ischemic stroke	Traumas	Pulmonary
Dilated CMO	Seizure	Osteomyelitis	Pulmonary edema
Aortic dissection	Cognitive impairment		Pulmonary hypertension
Infective endocarditis		Obstetrical	
	Dermatologic	Fetal growth restriction	Renal
Genitourinary	Picking/excoriations	Premature delivery	Myoglobulinuria
STIs	Cellulitis	Abruption	Necrotizing angiitis
	Abscesses		

^{*}Societal harms: environmental hazards/pollution, crime, violence.


Neurotoxicity (dopamine neurons)



^a PET scan was performed 80 days after detoxification.

Epidemiology

FIG. 27 Global quantity of amphetamine-type stimulants seized, 1998–2017





US National Survey on Drug use and Health: Prevalence of Illicit Drug Use

Table 1.6B Types of Illicit Drug Use in Lifetime, Past Year, and Past Month among Persons Aged 18 or Older: Percentages, 2015 and 2016


Drug	Lifetime (2015)	Lifetime (2016)	Past Year (2015)	Past Year (2016)	Past Month (2015)	Past Month (2016)
ILLICIT DRUGS ^{1,2}	51.2	51.1	17.9	18.2	10.2ª	10.9
Marijuana	16.0	47.0	12.6a	1/1	8 Vp	0.1
Cocaine	15.9	15.8	1.9	2.0	0.8	0.8
Crack	3.7	3.6	0.3	0.4	0.2	0.2
Heroin	2.1	2.0	0.3	0.4	0.1	0.2
Hallucinogens	16.5	16.7	1.7	1.8	0.5	0.5
LSD	10.3	10.5	0.5 ^b	0.7	0.1	0.1
PCP	2.6	2.6	0.0	0.0	0.0	0.0
Ecstasy	7.4	7.4	1.0	0.9	0.2	0.2
Inhalants	9 7a	9 1	0.4	0.5	0.1	0.2
Methamphetamine	5.9	5.9	0.7ª	0.6	0.4ª	0.3
Misuse of Psychotherapeutics ^{3,4}	nr	nr	1.2	7.1	2.4	2.4
Pain Relievers ⁴	nr	nr	4.7 ^a	4.3	1.4	1.3
Tranquilizers	nr	nr	2.3	2.3	0.7	0.7
Stimulants	nr	nr	2.0	2.1	0.6	0.7
Sedatives	nr	nr	0.6	0.6	0.2	0.2
OPIOIDS (HEROIN USE OR PAIN						
RELIEVER MISUSE) ⁴	nr	nr	4.8 ^a	4.5	1.5	1.4

Methamphetamine Lab Distribution in the US






Psychostimulant-related overdose deaths in US, 1999-2017




- Total psychostimulants (including methamphetamine)
- Psychostimulants and any opioid
- Psychostimulants without any opioid
- Psychostimulants and other synthetic opioids

Treatment

Approach to treatment for stimulant use disorder



CBT: cognitive-behavioral therapy.



Trial medications

Study Drug	Effect
Psychostimulants (dexamphetamine, methylphenidate)	9 RCTs: may decrease use, craving, and/or severity of addiction?
Topiramate	2 RCTs: may decrease use, and/or severity?
Mirtazapine	1 RCT: may decrease use?
Bupropion	5 RCTs: may decrease use?
Naltrexone	2 RCTs: may decrease use and/or craving?
Modafinil	3 RCTs: may decrease use?

^{*}Studies limited by retention, adherence, primary outcomes.

Treatment of Stimulant Use Disorder: Psychosocial Treatments

- 1. Contingency management
- Cognitive behavioural therapy
- 3. Motivational interviewing
- 4. Relapse prevention
- 5. Psychodynamic therapy
- 6. Combinations programs

- Overall small to moderate effects (dropout rates are typically >40%)
- Immediate effects noted, long-term benefits for meth use disorder not clear

Treatment of Stimulant Use Disorder: Psychosocial Treatments

Contingency Management

- Goal is to reduce reinforcement provided by drug use while simultaneously increasing reinforcement for healthier activities
- Applies contingencies in the form of reinforcement and consequences in order to reduce substance use
- Often uses a voucher-based system to give possible rewards for staying in treatment or remaining drug-free
- A 2016 systematic review found that contingency management helped to decrease use in a diverse group of substance use disorders, with a treatment effect that weakened but did not disappear following treatment



















BMC Public Health



Research article

Open Access

A public health response to the methamphetamine epidemic: the

Clinical responses to CM in PROP were similar to CM delivered in drug treatment programs. [...] Further expansion of programs like PROP could address the increasing needs for acceptable, feasible, and costeffective methamphetamine treatment in this group with exceptionally high rates of HIV-infection.

Steven Gibson - sgibson@magnetsf.org; Michael Siever - msiever@itsa.ucsf.edu; William D King - wdking37@yahoo.com; Uyen Kao - ubui@mednet.ucla.edu; Jeffrey Dang - jdang@mednet.ucla.edu

Published: 18 August 2006

BMC Public Health 2006, **6**:214 doi:10.1186/1471-2458-6-214

Received: 17 May 2006 Accepted: 18 August 2006

This article is available from: http://www.biomedcentral.com/1471-2458/6/214

^{*} Corresponding author

Conclusions

- The prevalence of methamphetamine use continues to rise and it is associated with numerous physical, psychiatric, and social harms
- Methamphetamine use is associated with an increased risk of contracting HIV and worse HIV treatment outcomes
- Evidence-based treatments are available for stimulant use disorder, psychosocial approaches (esp. CM) remain the gold standard and can be implemented in settings with high rates of HIV



paxton.bach@bccsu.ubc.ca

BRITISH COLUMBIA CENTRE ON

SUBSTANCE USE

St. Paul's Hospital 613 - 1081 Burrard Street Vancouver, BC Canada V6Z 1Y6 TEL: 604.806.8477 FAX: 604.806.8464









